Arca
Skip to content

Short bowel syndrome

Drug research and approvals for short bowel syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 20 studies of short bowel syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 4 approved and 12 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 20
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 4
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 20 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Sep 17, 2026A parallel-group treatment, phase 3, double-blind, randomized, 2-arm study to investigate the efficacy and safety of apraglutide compared with placebo in adult…APRAGLUTIDE (TA799, FE 203799)VECTIVBIO AGPending
Nov 26, 2025A 104-week, multicenter, open-label, single-arm, phase 3 extension trial investigating the long-term safety and efficacy of glepaglutide in adult patients with…GLEPAGLUTIDEZealand PharmaOngoing
Mar 17, 2022A 104-week, multicenter, single-arm, longterm, phase 3 extension trial investigating the safety and efficacy of glepaglutide in adult patients with short bowel…GLEPAGLUTIDEZealand PharmaClosed
May 16, 2019A double-blind phase 3 extension trial assessing the long term safety and efficacy of glepaglutide in patients with short bowel syndrome (sbs)GLEPAGLUTIDEZealand PharmaClosed
Oct 5, 2018A phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with…GLEPAGLUTIDEZealand PharmaClosed
Sep 30, 2016A prospective, open-label, long-term safety and efficacy study of teduglutide in pediatric patientswith short bowel syndrome who completed ted-c14-006REVESTIVETakeda Pharmaceuticals USAClosed
May 19, 2016A 24-week double-blind, safety, efficacy, and pharmacodynamic study investigating two doses of teduglutide in pediatric subjects through 17 years of age with…REVESTIVESHIRE-NPS PHARMACEUTICALS INC.Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 16
May 16, 2019GATTEXGATTEX® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are…Takeda Pharmaceuticals U.S.A., Inc.Approved
Dec 21, 2012GATTEXTreatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral supportTakeda Pharmaceuticals U.S.A., Inc.Approved
Jun 10, 2004NutreStoreTreatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human…Emmaus Medical, Inc.Approved
Dec 1, 2003ZorbtiveTreatment of short bowel syndrome in patients receiving specialized nutritional supportEMD Serono, Inc.Approved
Mar 9, 2023Arginine butyrateTreatment of Short Bowel SyndromeBaxter Healthcare CorporationDesignated
May 1, 2019human glucagon-like peptide-2 analogue linked to a human…Treatment of short bowel syndromeHanmi Pharmaceutical Co. Ltd.Designated
Dec 20, 2018apraglutideTreatment of short bowel syndrome (SBS)Ironwood Pharmaceuticals, Inc.Designated
Oct 11, 2018Glucagon-Like Peptide 2 fused to hyFcTreatment of short bowel syndromeGenexineDesignated
Oct 20, 2017glepaglutideTreatment of short bowel syndromeZealand Pharma A/SDesignated
Aug 2, 2017crofelemerTreatment of short bowel syndromeNapo Pharmaceuticals, Inc.Designated
Feb 14, 2017melatoninTreatment of short bowel syndromeWORPHMED SrlDesignated
Oct 7, 2015recombinant fusion protein comprising exenatide and XTENTreatment of short bowel syndrome.9 Meters Biopharma, Inc.Designated
Jun 1, 2015docosahexaenoic acidTreatment of short bowel syndromeMicelle BioPharma, Inc.Designated
Apr 6, 2015human insulin (rDNA)Treatment of short bowel syndrome (SBS).ELGAN Pharma Ltd.Designated
Dec 2, 2011opium tinctureTreatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatmentValeant Pharmaceuticals International, Inc.Designated

Medicines Authorised in the EU

Newest first
Jan 8, 2026Teduglutide Viatristeduglutide · genericViatris LimitedEMA ↗
Aug 30, 2012RevestiveteduglutideTakeda Pharmaceuticals International AG IrelandEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.